Ocular Safety and Usability Study for FYB203 PFS
NCT06708637 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2024-11-27
Summary
The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
Conditions
- Age-Related Macular Degeneration
- Branch Retinal Vein Occlusion with Macular Edema
- Central Retinal Vein Occlusion with Macular Edema
- Diabetic Macular Edema
- Diabetic Retinopathy
Interventions
- DRUG
-
FYB203 2 mg (0.05 mL of 40 mg/mL)
IVT administration of FYB203 in a PFS
Sponsors & Collaborators
-
Formycon AG
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-20
- Primary Completion
- 2024-10-08
- Completion
- 2024-10-08
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration
NCT01226628 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
NCT03846193 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
NCT03238963 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
NCT05569148 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
NCT02214628 ·Status: TERMINATED ·Phase: PHASE2
-
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
NCT03633084 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
NCT00709527 ·Status: COMPLETED ·Phase: PHASE1
-
Resistance to Antibiotics in Patients Receiving Eye Injections
NCT02126423 ·Status: COMPLETED
-
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447980 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
NCT02022501 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
NCT01027650 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
NCT06011798 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
NCT01624636 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
NCT02659098 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
NCT01301443 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
NCT00090532 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
NCT01922128 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
NCT06132035 ·Status: RECRUITING ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers
NCT05538949 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
NCT01678963 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
NCT00259753 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
NCT00913744 ·Status: COMPLETED ·Phase: PHASE2
-
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
NCT00877032 ·Status: COMPLETED ·Phase: PHASE1